aluates Reports

$ 0.0

Automative

Global Sickle Cell Anemia Therapeutics Market Research Report 2025

Published Date: August 2025

Report Code: QYRE-Auto-26Q12719

Global Sickle Cell Anemia Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Sickle Cell Anemia Therapeutics Market Research Report 2025

Code: QYRE-Auto-26Q12719

Report

August 2025

Pages:82

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Gamida Cell

GlycoMimetics

Pfizer Inc

Novartis

Bluebird bio

Prolong Pharmaceuticals

Modus Therapeutics

Sangamo BioSciences

Bioverativ

Imara

Ironwood Pharmaceuticals

Emmaus Medical

Novo Nordisk

CRISPR Therapeutics

Theravia

Sickle Cell Anemia Therapeutics Market Size

The global market for Sickle Cell Anemia Therapeutics was valued at US$ 4067 million in the year 2024 and is projected to reach a revised size of US$ 9988 million by 2031, growing at a CAGR of 13.7% during the forecast period.

Sickle Cell Anemia Therapeutics Market

Sickle cell disease (SCD) is a chronic, inherited blood disorder caused by a mutation in the beta-globin gene, leading to the production of abnormal hemoglobin called sickle hemoglobin (HbS). Under low-oxygen conditions, HbS polymerizes, causing red blood cells to assume a rigid, sickle shape. These deformed cells are prone to hemolysis and can block blood vessels, resulting in pain, anemia, and organ damage. Therapeutic approaches include pharmacological treatments (e.g., hydroxyurea, L-glutamine), gene therapy, hematopoietic stem cell transplantation, and supportive care.

Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Theravia, Gamida Cell, GlycoMimetics, etc. Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent. In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.The therapeutic landscape for sickle cell disease is rapidly evolving, with major pharmaceutical players (e.g., Pfizer, Novartis, Novo Nordisk) investing alongside specialized biotech firms (e.g., Bluebird Bio, CRISPR Therapeutics, Imara, Emmaus Medical). Approved treatments range from small-molecule agents like L-glutamine (Emmaus) to gene-based curative approaches such as Bluebird’s Zynteglo and CRISPR/Vertex’s Casgevy, marking a shift toward durable, potentially one-time interventions. Future development will prioritize expanding patient access to gene therapies, addressing long-term safety, and improving conditioning regimens for stem cell transplantation. Novel approaches, including anti-adhesion therapies (GlycoMimetics), nitric oxide modulators (Prolong), and macrophage-targeted solutions (Modus), are diversifying the pipeline. With ongoing clinical innovation and supportive regulatory momentum, the field is transitioning from symptomatic relief to functional cures, especially for underserved global populations.

This report aims to provide a comprehensive presentation of the global market for Sickle Cell Anemia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sickle Cell Anemia Therapeutics.

The Sickle Cell Anemia Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Sickle Cell Anemia Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Sickle Cell Anemia Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Sickle Cell Anemia Therapeutics Market Report

Report Metric	Details
Report Name	Sickle Cell Anemia Therapeutics Market
Accounted market size in year	US$ 4067 million
Forecasted market size in 2031	US$ 9988 million
CAGR	13.7%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Blood Transfusion Pharmacotherapy Bone Marrow Transplant
Segment by Application	Child Adult
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Emmaus Medical, Theravia, Pfizer, Novartis, Bluebird Bio, Novo Nordisk, Gamida Cell, CRISPR Therapeutics, GlycoMimetics, Prolong Pharmaceuticals, Modus Therapeutics, Sangamo Biosciences, Bioverativ, Imara, Ironwood Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sickle Cell Anemia Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Sickle Cell Anemia Therapeutics Market growing?

Ans: The Sickle Cell Anemia Therapeutics Market witnessing a CAGR of 13.7% during the forecast period 2025-2031.

What is the Sickle Cell Anemia Therapeutics Market size in 2031?

Ans: The Sickle Cell Anemia Therapeutics Market size in 2031 will be US$ 9988 million.

What is the Sickle Cell Anemia Therapeutics Market share by type?

Ans: In terms of product, Blood Transfusion is the largest segment, with a share over 35%.

Who are the main players in the Sickle Cell Anemia Therapeutics Market report?

Ans: The main players in the Sickle Cell Anemia Therapeutics Market are Emmaus Medical, Theravia, Pfizer, Novartis, Bluebird Bio, Novo Nordisk, Gamida Cell, CRISPR Therapeutics, GlycoMimetics, Prolong Pharmaceuticals, Modus Therapeutics, Sangamo Biosciences, Bioverativ, Imara, Ironwood Pharmaceuticals

What are the Application segmentation covered in the Sickle Cell Anemia Therapeutics Market report?

Ans: The Applications covered in the Sickle Cell Anemia Therapeutics Market report are Child, Adult

What are the Type segmentation covered in the Sickle Cell Anemia Therapeutics Market report?

Ans: The Types covered in the Sickle Cell Anemia Therapeutics Market report are Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant

Recommended Reports

Anemia & Blood Disorders

Hemoglobin & Transfusion

Therapeutics & Gene Therapy

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Blood Transfusion

1.2.3 Pharmacotherapy

1.2.4 Bone Marrow Transplant

1.3 Market by Application

1.3.1 Global Sickle Cell Anemia Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Child

1.3.3 Adult

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Sickle Cell Anemia Therapeutics Market Perspective (2020-2031)

2.2 Global Sickle Cell Anemia Therapeutics Growth Trends by Region

2.2.1 Global Sickle Cell Anemia Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Sickle Cell Anemia Therapeutics Historic Market Size by Region (2020-2025)

2.2.3 Sickle Cell Anemia Therapeutics Forecasted Market Size by Region (2026-2031)

2.3 Sickle Cell Anemia Therapeutics Market Dynamics

2.3.1 Sickle Cell Anemia Therapeutics Industry Trends

2.3.2 Sickle Cell Anemia Therapeutics Market Drivers

2.3.3 Sickle Cell Anemia Therapeutics Market Challenges

2.3.4 Sickle Cell Anemia Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Sickle Cell Anemia Therapeutics Players by Revenue

3.1.1 Global Top Sickle Cell Anemia Therapeutics Players by Revenue (2020-2025)

3.1.2 Global Sickle Cell Anemia Therapeutics Revenue Market Share by Players (2020-2025)

3.2 Global Top Sickle Cell Anemia Therapeutics Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Sickle Cell Anemia Therapeutics Revenue

3.4 Global Sickle Cell Anemia Therapeutics Market Concentration Ratio

3.4.1 Global Sickle Cell Anemia Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Sickle Cell Anemia Therapeutics Revenue in 2024

3.5 Global Key Players of Sickle Cell Anemia Therapeutics Head office and Area Served

3.6 Global Key Players of Sickle Cell Anemia Therapeutics, Product and Application

3.7 Global Key Players of Sickle Cell Anemia Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Sickle Cell Anemia Therapeutics Breakdown Data by Type

4.1 Global Sickle Cell Anemia Therapeutics Historic Market Size by Type (2020-2025)

4.2 Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Type (2026-2031)

5 Sickle Cell Anemia Therapeutics Breakdown Data by Application

5.1 Global Sickle Cell Anemia Therapeutics Historic Market Size by Application (2020-2025)

5.2 Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Sickle Cell Anemia Therapeutics Market Size (2020-2031)

6.2 North America Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Sickle Cell Anemia Therapeutics Market Size by Country (2020-2025)

6.4 North America Sickle Cell Anemia Therapeutics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Sickle Cell Anemia Therapeutics Market Size (2020-2031)

7.2 Europe Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Sickle Cell Anemia Therapeutics Market Size by Country (2020-2025)

7.4 Europe Sickle Cell Anemia Therapeutics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size (2020-2031)

8.2 Asia-Pacific Sickle Cell Anemia Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Region (2020-2025)

8.4 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Sickle Cell Anemia Therapeutics Market Size (2020-2031)

9.2 Latin America Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Sickle Cell Anemia Therapeutics Market Size by Country (2020-2025)

9.4 Latin America Sickle Cell Anemia Therapeutics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size (2020-2031)

10.2 Middle East & Africa Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2020-2025)

10.4 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Emmaus Medical

11.1.1 Emmaus Medical Company Details

11.1.2 Emmaus Medical Business Overview

11.1.3 Emmaus Medical Sickle Cell Anemia Therapeutics Introduction

11.1.4 Emmaus Medical Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.1.5 Emmaus Medical Recent Development

11.2 Theravia

11.2.1 Theravia Company Details

11.2.2 Theravia Business Overview

11.2.3 Theravia Sickle Cell Anemia Therapeutics Introduction

11.2.4 Theravia Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.2.5 Theravia Recent Development

11.3 Pfizer

11.3.1 Pfizer Company Details

11.3.2 Pfizer Business Overview

11.3.3 Pfizer Sickle Cell Anemia Therapeutics Introduction

11.3.4 Pfizer Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.3.5 Pfizer Recent Development

11.4 Novartis

11.4.1 Novartis Company Details

11.4.2 Novartis Business Overview

11.4.3 Novartis Sickle Cell Anemia Therapeutics Introduction

11.4.4 Novartis Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.4.5 Novartis Recent Development

11.5 Bluebird Bio

11.5.1 Bluebird Bio Company Details

11.5.2 Bluebird Bio Business Overview

11.5.3 Bluebird Bio Sickle Cell Anemia Therapeutics Introduction

11.5.4 Bluebird Bio Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.5.5 Bluebird Bio Recent Development

11.6 Novo Nordisk

11.6.1 Novo Nordisk Company Details

11.6.2 Novo Nordisk Business Overview

11.6.3 Novo Nordisk Sickle Cell Anemia Therapeutics Introduction

11.6.4 Novo Nordisk Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.6.5 Novo Nordisk Recent Development

11.7 Gamida Cell

11.7.1 Gamida Cell Company Details

11.7.2 Gamida Cell Business Overview

11.7.3 Gamida Cell Sickle Cell Anemia Therapeutics Introduction

11.7.4 Gamida Cell Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.7.5 Gamida Cell Recent Development

11.8 CRISPR Therapeutics

11.8.1 CRISPR Therapeutics Company Details

11.8.2 CRISPR Therapeutics Business Overview

11.8.3 CRISPR Therapeutics Sickle Cell Anemia Therapeutics Introduction

11.8.4 CRISPR Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.8.5 CRISPR Therapeutics Recent Development

11.9 GlycoMimetics

11.9.1 GlycoMimetics Company Details

11.9.2 GlycoMimetics Business Overview

11.9.3 GlycoMimetics Sickle Cell Anemia Therapeutics Introduction

11.9.4 GlycoMimetics Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.9.5 GlycoMimetics Recent Development

11.10 Prolong Pharmaceuticals

11.10.1 Prolong Pharmaceuticals Company Details

11.10.2 Prolong Pharmaceuticals Business Overview

11.10.3 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Introduction

11.10.4 Prolong Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.10.5 Prolong Pharmaceuticals Recent Development

11.11 Modus Therapeutics

11.11.1 Modus Therapeutics Company Details

11.11.2 Modus Therapeutics Business Overview

11.11.3 Modus Therapeutics Sickle Cell Anemia Therapeutics Introduction

11.11.4 Modus Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.11.5 Modus Therapeutics Recent Development

11.12 Sangamo Biosciences

11.12.1 Sangamo Biosciences Company Details

11.12.2 Sangamo Biosciences Business Overview

11.12.3 Sangamo Biosciences Sickle Cell Anemia Therapeutics Introduction

11.12.4 Sangamo Biosciences Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.12.5 Sangamo Biosciences Recent Development

11.13 Bioverativ

11.13.1 Bioverativ Company Details

11.13.2 Bioverativ Business Overview

11.13.3 Bioverativ Sickle Cell Anemia Therapeutics Introduction

11.13.4 Bioverativ Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.13.5 Bioverativ Recent Development

11.14 Imara

11.14.1 Imara Company Details

11.14.2 Imara Business Overview

11.14.3 Imara Sickle Cell Anemia Therapeutics Introduction

11.14.4 Imara Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.14.5 Imara Recent Development

11.15 Ironwood Pharmaceuticals

11.15.1 Ironwood Pharmaceuticals Company Details

11.15.2 Ironwood Pharmaceuticals Business Overview

11.15.3 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Introduction

11.15.4 Ironwood Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025)

11.15.5 Ironwood Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Gamida Cell

GlycoMimetics

Pfizer Inc

Novartis

Bluebird bio

Prolong Pharmaceuticals

Modus Therapeutics

Sangamo BioSciences

Bioverativ

Imara

Ironwood Pharmaceuticals

Emmaus Medical

Novo Nordisk

CRISPR Therapeutics

Theravia

List of Tables

Table 1. Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Blood Transfusion

Table 3. Key Players of Pharmacotherapy

Table 4. Key Players of Bone Marrow Transplant

Table 5. Global Sickle Cell Anemia Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Sickle Cell Anemia Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Sickle Cell Anemia Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Sickle Cell Anemia Therapeutics Market Share by Region (2020-2025)

Table 9. Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Sickle Cell Anemia Therapeutics Market Share by Region (2026-2031)

Table 11. Sickle Cell Anemia Therapeutics Market Trends

Table 12. Sickle Cell Anemia Therapeutics Market Drivers

Table 13. Sickle Cell Anemia Therapeutics Market Challenges

Table 14. Sickle Cell Anemia Therapeutics Market Restraints

Table 15. Global Sickle Cell Anemia Therapeutics Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Sickle Cell Anemia Therapeutics Market Share by Players (2020-2025)

Table 17. Global Top Sickle Cell Anemia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sickle Cell Anemia Therapeutics as of 2024)

Table 18. Ranking of Global Top Sickle Cell Anemia Therapeutics Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Sickle Cell Anemia Therapeutics Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Sickle Cell Anemia Therapeutics, Headquarters and Area Served

Table 21. Global Key Players of Sickle Cell Anemia Therapeutics, Product and Application

Table 22. Global Key Players of Sickle Cell Anemia Therapeutics, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Sickle Cell Anemia Therapeutics Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Type (2020-2025)

Table 26. Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Type (2026-2031)

Table 28. Global Sickle Cell Anemia Therapeutics Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2020-2025)

Table 30. Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2026-2031)

Table 32. North America Sickle Cell Anemia Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Sickle Cell Anemia Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Sickle Cell Anemia Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Sickle Cell Anemia Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Sickle Cell Anemia Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Sickle Cell Anemia Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Sickle Cell Anemia Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Sickle Cell Anemia Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Sickle Cell Anemia Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Sickle Cell Anemia Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Sickle Cell Anemia Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 47. Emmaus Medical Company Details

Table 48. Emmaus Medical Business Overview

Table 49. Emmaus Medical Sickle Cell Anemia Therapeutics Product

Table 50. Emmaus Medical Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 51. Emmaus Medical Recent Development

Table 52. Theravia Company Details

Table 53. Theravia Business Overview

Table 54. Theravia Sickle Cell Anemia Therapeutics Product

Table 55. Theravia Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 56. Theravia Recent Development

Table 57. Pfizer Company Details

Table 58. Pfizer Business Overview

Table 59. Pfizer Sickle Cell Anemia Therapeutics Product

Table 60. Pfizer Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 61. Pfizer Recent Development

Table 62. Novartis Company Details

Table 63. Novartis Business Overview

Table 64. Novartis Sickle Cell Anemia Therapeutics Product

Table 65. Novartis Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 66. Novartis Recent Development

Table 67. Bluebird Bio Company Details

Table 68. Bluebird Bio Business Overview

Table 69. Bluebird Bio Sickle Cell Anemia Therapeutics Product

Table 70. Bluebird Bio Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 71. Bluebird Bio Recent Development

Table 72. Novo Nordisk Company Details

Table 73. Novo Nordisk Business Overview

Table 74. Novo Nordisk Sickle Cell Anemia Therapeutics Product

Table 75. Novo Nordisk Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 76. Novo Nordisk Recent Development

Table 77. Gamida Cell Company Details

Table 78. Gamida Cell Business Overview

Table 79. Gamida Cell Sickle Cell Anemia Therapeutics Product

Table 80. Gamida Cell Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 81. Gamida Cell Recent Development

Table 82. CRISPR Therapeutics Company Details

Table 83. CRISPR Therapeutics Business Overview

Table 84. CRISPR Therapeutics Sickle Cell Anemia Therapeutics Product

Table 85. CRISPR Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 86. CRISPR Therapeutics Recent Development

Table 87. GlycoMimetics Company Details

Table 88. GlycoMimetics Business Overview

Table 89. GlycoMimetics Sickle Cell Anemia Therapeutics Product

Table 90. GlycoMimetics Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 91. GlycoMimetics Recent Development

Table 92. Prolong Pharmaceuticals Company Details

Table 93. Prolong Pharmaceuticals Business Overview

Table 94. Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Product

Table 95. Prolong Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 96. Prolong Pharmaceuticals Recent Development

Table 97. Modus Therapeutics Company Details

Table 98. Modus Therapeutics Business Overview

Table 99. Modus Therapeutics Sickle Cell Anemia Therapeutics Product

Table 100. Modus Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 101. Modus Therapeutics Recent Development

Table 102. Sangamo Biosciences Company Details

Table 103. Sangamo Biosciences Business Overview

Table 104. Sangamo Biosciences Sickle Cell Anemia Therapeutics Product

Table 105. Sangamo Biosciences Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 106. Sangamo Biosciences Recent Development

Table 107. Bioverativ Company Details

Table 108. Bioverativ Business Overview

Table 109. Bioverativ Sickle Cell Anemia Therapeutics Product

Table 110. Bioverativ Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 111. Bioverativ Recent Development

Table 112. Imara Company Details

Table 113. Imara Business Overview

Table 114. Imara Sickle Cell Anemia Therapeutics Product

Table 115. Imara Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 116. Imara Recent Development

Table 117. Ironwood Pharmaceuticals Company Details

Table 118. Ironwood Pharmaceuticals Business Overview

Table 119. Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Product

Table 120. Ironwood Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2020-2025) & (US$ Million)

Table 121. Ironwood Pharmaceuticals Recent Development

Table 122. Research Programs/Design for This Report

Table 123. Key Data Information from Secondary Sources

Table 124. Key Data Information from Primary Sources

Table 125. Authors List of This Report

List of Figures

Figure 1. Sickle Cell Anemia Therapeutics Picture

Figure 2. Global Sickle Cell Anemia Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Sickle Cell Anemia Therapeutics Market Share by Type: 2024 VS 2031

Figure 4. Blood Transfusion Features

Figure 5. Pharmacotherapy Features

Figure 6. Bone Marrow Transplant Features

Figure 7. Global Sickle Cell Anemia Therapeutics Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Sickle Cell Anemia Therapeutics Market Share by Application: 2024 VS 2031

Figure 9. Child Case Studies

Figure 10. Adult Case Studies

Figure 11. Sickle Cell Anemia Therapeutics Report Years Considered

Figure 12. Global Sickle Cell Anemia Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Sickle Cell Anemia Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Sickle Cell Anemia Therapeutics Market Share by Region: 2024 VS 2031

Figure 15. Global Sickle Cell Anemia Therapeutics Market Share by Players in 2024

Figure 16. Global Sickle Cell Anemia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 17. The Top 10 and 5 Players Market Share by Sickle Cell Anemia Therapeutics Revenue in 2024

Figure 18. North America Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Sickle Cell Anemia Therapeutics Market Share by Country (2020-2031)

Figure 20. United States Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Sickle Cell Anemia Therapeutics Market Share by Country (2020-2031)

Figure 24. Germany Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Ireland Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Sickle Cell Anemia Therapeutics Market Share by Region (2020-2031)

Figure 32. China Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia & New Zealand Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Sickle Cell Anemia Therapeutics Market Share by Country (2020-2031)

Figure 40. Mexico Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Sickle Cell Anemia Therapeutics Market Share by Country (2020-2031)

Figure 44. Israel Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Sickle Cell Anemia Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Emmaus Medical Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 48. Theravia Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 49. Pfizer Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 50. Novartis Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 51. Bluebird Bio Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 52. Novo Nordisk Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 53. Gamida Cell Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 54. CRISPR Therapeutics Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 55. GlycoMimetics Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 56. Prolong Pharmaceuticals Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 57. Modus Therapeutics Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 58. Sangamo Biosciences Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 59. Bioverativ Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 60. Imara Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 61. Ironwood Pharmaceuticals Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2020-2025)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Gene Therapy for Sickle Cell Disease Market Research Report 2024

Sickle Cell Anemia Testing Screening Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Hemoglobinopathies Market Insights Forecast to 2030

Global Hemoglobinopathy Treatment Market Insights Forecast to 2030

Global Hemoglobinopathy Testing Services Market Insights Forecast to 2030

Global Hemoglobinopathy Drugs Market Insights Forecast to 2030

Global Sickle Cell Disease Diagnosis Market Insights Forecast to 2030

Myelodysplastic Syndrome MDS Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Sickle Cell Disease Diagnosis and Treatment Market Research Report 2025

Global Bench top HbA1c Analyzers Market Insights Forecast to 2030

Global Transfusion dependent Anemia Treatment Market Research Report 2025

Gaucher Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Metachromatic Leukodystrophy Treatment Market Research Report 2025

Global Anemia Treatment Drugs Market Insights Forecast to 2030

Global Thalassemia Gene Test Kit Market Research Report 2024

Global Congenital Heart Diseases Market Research Report 2024

Global Direct to consumer Disease Risk and Health Genetic Test Market Insights Forecast to 2030

Global Chromatography Hemoglobin Testing Market Research Report 2024

Alpha Thalassemia Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions